SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026)
SELLAS Life Sciences' (SLS) quarterly Change in Account Payables came in at $685000.0 in Q1 2026, up 147.29% year-on-year from $277000.0 in Q1 2025, and up 3.79% on a QoQ basis from $660000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Change in Account Payables data on file, last reported at $685000.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 147.29% year-over-year to $685000.0 in Q1 2026; TTM through Mar 2026 was -$127000.0, a 96.54% increase from a year earlier, with the FY2025 full-year figure at -$535000.0, up 74.99% from the prior year.
- Change in Account Payables for Q1 2026 stood at $685000.0, up from $660000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for SLS reached as high as $1.8 million in Q1 2024 and fell as low as -$1.8 million in Q3 2024.
- Historically, Change in Account Payables has averaged $89705.9 across 5 years, with a median of $528000.0 in 2022.
- Across the five-year window, Change in Account Payables tumbled 550.56% in 2022 and surged 735.92% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $1.2 million in 2022, then gained by 7.15% to $1.3 million in 2023, then tumbled by 184.83% to -$1.1 million in 2024, then surged by 159.03% to $660000.0 in 2025, then increased by 3.79% to $685000.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $685000.0 in Q1 2026, $660000.0 in Q4 2025, and -$1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - | 685,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 685,000.00 |
| Mar 31, 2026 | 685,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Sep 30, 2025 | -1.03 Mn |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -441,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | -1.77 Mn |
| Sep 30, 2024 | -1.77 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Dec 31, 2023 | 1.32 Mn |